Richard Porter

Dr. Richard Porter was named Chief Business Officer in April 2022. He is responsible for global business development, corporate strategic planning, market access and commercial planning.

Dr. Porter joined uniQure as General Manager of the Corlieve subsidiary following the acquisition of Corlieve Therapeutics in July 2021. He was the founder and CEO of Corlieve.

He brings more than 25 years of R&D experience to uniQure, having previously served as the COO of Therachon until its acquisition by Pfizer. Previously he was at Roche in positions of increasing responsibility, most recently as the Global Head of Scientific Business Strategy and Operations for Neuroscience Ophthalmology and Rare Diseases directing the strategic and operational activities of the department. He has also served as a Product General Manager of the Emerging Business Unit at Shire Pharmaceuticals and has held scientific leadership positions at Vernalis and ASTRA.

Richard earned his Ph.D. in neuropharmacology from Southampton University (UK) and conducted his postdoctoral training at the Strong Memorial Hospital, University of Rochester, NY (USA) and the University of Oxford (UK).